NDAINTRAVENOUSPOWDER
Approved
Sep 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
16
Data completeness
4/8 — Partial
FOSAPREPITANT DIMEGLUMINE (fosaprepitant) by Teva is accordingly, its antiemetic effects are attributable to aprepitant. First approved in 2019.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Fosaprepitant dimeglumine is an intravenous NK1 receptor antagonist prodrug that is converted to aprepitant, a selective high-affinity antagonist of substance P/neurokinin 1 receptors in the central nervous system. It is indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV), particularly in combination with 5-HT3 antagonists and corticosteroids. The drug crosses the blood-brain barrier and inhibits both acute and delayed phases of emesis induced by highly emetogenic chemotherapy agents such as cisplatin.
Peak
Product is at peak commercial maturity with moderate competitive pressure (30/100); teams are likely focused on market defense and optimization rather than growth expansion.
Mechanism of Action
accordingly, its antiemetic effects are attributable to aprepitant. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK 1 ) receptors. Aprepitant has little or no affinity for serotonin (5-HT 3 ), dopamine, and corticosteroid receptors, the targets of existing…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (16)
Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)
Started Sep 2019
103 enrolled
Chemotherapy-induced Nausea and Vomiting
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Started Nov 2018
690 enrolled
Malignant Neoplasm
Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)
Started Sep 2015
75 enrolled
Chemotherapy-induced Nausea and Vomiting
Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy
Started Apr 2015
150 enrolled
Non-small Cell Lung CancerVomitingNausea+1 more
Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma
Started Sep 2013
13 enrolled
Chemotherapy-induced Nausea and Vomiting
Worked on FOSAPREPITANT DIMEGLUMINE at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.